A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.
Combined with the two vaccines currently in circulation, the U.S. could have three vaccines that are all highly effective at preventing death or hospitalization due to COVID-19.
Despite that promising news, NPR's
Richard Harris reports on why
the journey to herd immunity still won't be easy.
And
Rae Ellen Bichelle goes inside a Colorado long-term care facility that has vaccinated nearly all of its residents. They say the initial steps to a return to normalcy feel great.
Additional reporting in this episode on
the spread of coronavirus variants from NPR's
Allison Aubrey.
In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.Email us at
[email protected].
Learn more about sponsor message choices:
podcastchoices.com/adchoicesNPR Privacy Policy